FDA warned Unexo Lifesciences over serious CGMP violations, including data integrity failures and torn batch records for U.S.-bound drugs.
What happened
FDA inspected Unexo's drug manufacturing facility from May 1 to 14, 2024. Investigators found torn batch production records in plastic bags on the rooftop, missing batch records for U.S.-market patches, records retrospectively prepared for the inspection, incomplete laboratory raw data, and computer controls that let a QC analyst manipulate results, dates, and COA stamp approvals. FDA also observed unclean air conditioner vents above production areas and said inspection access was limited when a computer was taken home and files were deleted from a laptop.
What FDA found
The quality control unit did not adequately oversee data reliability and CGMP compliance.
21 CFR 211.22Batch production and control records were incomplete, torn, missing, or retrospectively prepared for U.S.-market batches.
21 CFR 211.188Laboratory records lacked complete raw data needed to support release testing.
21 CFR 211.194(a)Computer system controls allowed an analyst to manipulate results, dates, and vendor stamp images on certificate of analysis records.
21 CFR 211.68(b)Air conditioner vents above production areas were unclean, creating a contamination risk.
21 CFR 211.67(a)FDA's access to records was limited when a computer was unavailable and files were deleted before review.
section 501(j) of the FD&C Act
What FDA wants
FDA asks Unexo to provide a comprehensive data integrity investigation, risk assessment, CAPA plan, documentation and quality unit assessments, cleaning assessment and CAPA, and a recall update within 15 working days; it also asks the firm to notify FDA before resuming U.S. drug manufacturing.
Who should pay attention
- U.S. distributors and pharmacies handling Unexo-made patches
- companies sourcing drugs from Unexo
- quality teams managing third-party COAs and electronic records
This is a summary. Read the original letter on fda.gov.